Rxivist logo

Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder

By K. Häkkinen, JI. Kiiski, M. Lähteenvuo, T. Jukuri, K. Suokas, J. Niemi-Pynttäri, T. Kieseppä, T. Männynsalo, A. Wegelius, W. Haaki, K. Lahdensuo, R. Kajanne, M.A. Kaunisto, A. Tuulio-Henriksson, O. Kampman, Jarmo Hietala, J. Veijola, J. Lönnqvist, Erkki Isometsä, T. Paunio, J. Suvisaari, E. Kalso, M. Niemi, J. Tiihonen, Mark J Daly, A Palotie, AV Ahola-Olli

Posted 16 Nov 2020
medRxiv DOI: 10.1101/2020.11.13.20227058

PurposeWe constructed a CYP2D6 copy-number imputation panel by combining copy-number information to GWAS chip data. In addition, we report frequencies of key pharmacogenetic variants in individuals with a psychotic disorder from the genetically bottle-necked population of Finland. MethodsWe combined GWAS chip and CYP2D6 copy-number variation (CNV) data from the Breast Cancer Pain Genetics study (BrePainGen) to construct an imputation panel (N=902) for CYP2D6 CNV. The resulting data set was used as a CYP2D6 CNV imputation panel in 9,262 non-related individuals passing genotype data quality control procedures. The panel performance was evaluated by genotyping the CNV from a subset (N=297) of SUPER-Finland participants. ResultsCYP2D6 CNV was imputed correctly in 272 (92%) individuals. Sensitivity and specificity for detecting a duplication were 0.986 and 0.946, respectively. Sensitivity and specificity for detecting a deletion using imputation were 0.886 and 0.966, respectively. Based on imputation, the frequency of a CYP2D6 duplication and deletion in the whole SUPER-Finland sample with 9,262 non-related individuals passing quality control were 8.5% and 2.7%, respectively. We confirm the higher frequency of CYP2D6 ultrarapid metabolizers in Finland compared with non-Finnish Europeans. Additionally, we confirm a 21-fold enrichment of the UGT1A1 decreased function variant rs4148323 (also known as 211G>A, G71R or UGT1A1*6) in Finland compared with non-Finnish Europeans. Similarly, the NUDT15 variant rs116855232 was highly enriched in Finland. ConclusionOur results demonstrate that imputation of CYP2D6 CNV is possible. The methodology is not accurate enough to be used in clinical decision making, but it enables studying CYP2D6 in large biobanks with genome-wide data. In addition, it allows for researchers to recontact patients with certain pharmacogenetic variations through biobanks. We show that bottle-necked populations may have pharmacogenetically important variants with allele frequencies very different from the main ancestral group. Future studies should assess whether these differences are large enough to cause clinically significant changes in trial results across different ancestral groups.

Download data

  • Downloaded 531 times
  • Download rankings, all-time:
    • Site-wide: 68,437
    • In genetic and genomic medicine: 332
  • Year to date:
    • Site-wide: 34,191
  • Since beginning of last month:
    • Site-wide: 34,563

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide